Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 16
Emerging Approaches and Key Takeaways in R/R MM: Insights from ASCO 2025
Panelists discuss how evolving therapeutic strategies, including the use of quadruplet regimens and emerging trispecific antibodies, may lead to functional cures in multiple myeloma and shift treatment goals toward finite-duration therapy.
Sequencing GPRC5D vs BCMA Therapies and Dual Targeting
The optimal sequencing of BCMA- and GPRC5D-directed therapies remains an open question. While most patients currently receive BCMA-targeting agents first, some may benefit from beginning with GPRC5D therapies due to disease burden or logistical concerns.
Using talquetamab as a bridging strategy before CAR T therapy is gaining interest, with washout periods of at least 1 month commonly used to mitigate immune interference. This approach provides disease control and preserves future treatment options.
Promising early data from bispecifics targeting both BCMA and GPRC5D simultaneously suggest dual targeting may enhance efficacy and prevent antigen escape. These innovations signal a new era in multiantigen immunotherapy for multiple myeloma.
Related Content:
